Edgewise Q2 net loss $57.3M; completes sevasemten sale to Servier for up to $2.65B

Edgewise Therapeutics, Inc.

2026-Q2 EPS reported -$0.99

Net loss $57.3M ($0.53/share) vs $36.1M ($0.34) in Q2 2025; R&D $47.5M, G&A $14.4M.
Completed sale of sevasemten and muscular dystrophy business to Servier for $1.55B upfront + up to $1.1B milestones (closed July 2026).
Cash $460.7M at June 30; pro forma $2.01B after sale proceeds (pre-tax/transaction costs).
Positive top-line Phase 2 CIRRUS-HCM data for EDG-7500 in HCM; Phase 3 expected Q4 2026.
EDG-15400 Phase 1 completed; Phase 2 in HFpEF expected H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.